Corinne Johnson

“Maybe as you look at business development, you've been highlighting the importance of relatively near-term revenues, But I'm curious where are the paths to earnings accretion factors in for deals that you might consider.”

“Maybe could you just speak to the market opportunity for the subcutaneous product? If you're able to bring a 12-week versus 8-week formulation to the market, do you see that as kind of meaningfully different in terms of your ability to gain share in that currently untapped population?”

“Maybe you could just quantify a bit more of the reimbursement dynamics here for these HO patients that are getting on therapy and translate that to how we should think about maybe net price per patient as this becomes a bigger portion of contribution to revenue.”

“I was just curious if you could talk a little bit about the reauthorization processes you saw for pernicity in 1Q and if you could provide any kind of commentary on reimbursement trends you're seeing in that population.”

“Maybe you mentioned this study for BOVA and that the FDA was pretty explicit that new molecules would require a year-long Phase III, I guess.”